KLOW (80 mg)

Sponsored

At a Glance

KLOW is an 80 mg lyophilised blend containing GHK-Cu (50 mg) + TB-500 (10 mg) + BPC-157 (10 mg) + KPV (10 mg). It builds on the GLOW formula by adding KPV — a potent anti-inflammatory tripeptide — making it the most comprehensive blend for recovery contexts involving gut or systemic immune involvement alongside tissue injury.[1][2]

• Reconstitute: Add 3.0 mL bacteriostatic water → 26.7 mg/mL concentration.
• Easy measuring: At 26.7 mg/mL on a U-100 syringe, 1 unit = 0.01 mL ≈ 267 mcg total blend (~167 mcg GHK-Cu + ~33 mcg each TB-500, BPC-157, KPV).
• Dosing: Titrate up over the cycle — start 7.5 units (~2,000 mcg) once daily, build to a 22.5-unit (~6,000 mcg) peak at weeks 5–8, then settle to a 15-unit (~4,000 mcg) maintenance dose. Subcutaneous, once daily.
• Cycle: 8–12 weeks standard; optional extension to 16 weeks.
• Storage: Lyophilised: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C; use within 4 weeks (14–28 days). Note: KLOW solution appears blue due to the GHK-Cu copper chelation — this is normal.

Overview

• Composition: GHK-Cu 50 mg + TB-500 10 mg + BPC-157 10 mg + KPV 10 mg (4:1:1:1 ratio) in an 80 mg lyophilised vial.
• Goal: Comprehensive tissue repair with additional gut-lining and systemic anti-inflammatory support via KPV.[1][2]
• Schedule: Once-daily SC injection on an escalating 8–12 week course (optional 16 weeks), titrating up to a peak at weeks 5–8 then tapering to maintenance.
• Reconstitution: 3.0 mL BAC water per 80 mg vial → 26.7 mg/mL.
• Storage: Lyophilised at −20 °C; reconstituted at 2–8 °C; use within 4 weeks.

What You’ll Need

Plan around a once-daily injection across the full course. Quantities scale with cycle length:

• Insulin syringes (U-100): one fresh syringe per injection (once daily). A 0.5 mL / 50-unit syringe is the most comfortable fit across all phases, since the weeks 5–8 peak draws 22.5 units (0.225 mL).
• Bacteriostatic water: 3.0 mL per vial — one 10 mL bottle covers up to 3 vials.
• Alcohol swabs: 2 per injection (vial stopper + skin).

How to Reconstitute

1. Allow frozen lyophilised vial to reach room temperature (10–15 minutes).
2. Draw 3.0 mL bacteriostatic water with a sterile syringe.
3. Inject slowly down the inner vial wall to minimise foaming; do not inject directly onto the powder cake.
4. Gently swirl or roll until fully dissolved — do not shake. Note: KLOW solution will appear blue due to the copper chelation of GHK-Cu; this is normal and expected.
5. Label with reconstitution date and all four component names; refrigerate at 2–8 °C, protected from light. Use within 4 weeks.

Dosing Schedule

Begin at the half-dose starting phase, then escalate. The schedule titrates GHK-Cu and the supporting peptides together in fixed 4:1:1:1 proportion as the total volume increases.

Frequency: Inject once daily subcutaneously throughout. Start at 7.5 units for the first 1–2 weeks to assess tolerability, raise to 15 units for weeks 3–4, hold the 22.5-unit peak through weeks 5–8, then taper to the 15-unit maintenance dose for weeks 9–12. A 16-week course holds maintenance through weeks 13–16.

Cycle structure: A complete 8–12 week course (optionally 16). Reassess healing progress at the end of the course before deciding on a repeat cycle.

Half-unit marks: 7.5 and 22.5 units fall on half-unit lines. Use a syringe with half-unit markings, or round to the nearest whole unit (8 and 22–23) — the small variance is not clinically meaningful at these volumes.

Protocol Details

• Weeks 1–2 (starting): ~2,000 mcg (7.5 units / 0.075 mL) once daily — half-dose tolerability phase.[2]
• Weeks 3–4 (build): ~4,000 mcg (15 units / 0.15 mL) once daily.
• Weeks 5–8 (peak): ~6,000 mcg (22.5 units / 0.225 mL) once daily.
• Weeks 9–12 (maintenance): ~4,000 mcg (15 units / 0.15 mL) once daily.
• Each peak injection delivers: ~3,750 mcg GHK-Cu + ~750 mcg TB-500 + ~750 mcg BPC-157 + ~750 mcg KPV.
• Injection site: Abdomen, thigh, or upper arm (rotate daily). For injuries with a strong local component, proximity to the injury site enhances BPC-157's local effects.

Syringe Math

With 3.0 mL of bacteriostatic water in the 80 mg vial:

• Total concentration: 26.7 mg/mL → 267 mcg per unit (0.01 mL) on a U-100 syringe.
• GHK-Cu: 16.7 mg/mL → ~167 mcg per unit.
• TB-500 / BPC-157 / KPV: 3.33 mg/mL each → ~33 mcg per unit each.
• So 1 unit (0.01 mL) delivers ~167 mcg GHK-Cu plus ~33 mcg of each supporting peptide. Multiply by the units in each phase to read off the per-component dose.

Storage

• Lyophilised: Store at −20 °C (−4 °F) or below; protect from moisture and light.
• Reconstituted: Refrigerate at 2–8 °C. Do not freeze. Use within 4 weeks (14–28 days); avoid repeated freeze–thaw cycles, and let the vial reach room temperature before drawing to reduce condensation.
• Blue colour: GHK-Cu copper chelation gives the solution a characteristic blue colour — inspect for clarity but do not expect the colourless appearance of other peptides.

How KLOW Works

KLOW combines four peptides into a single coordinated repair and anti-inflammatory protocol:

• GHK-Cu (50 mg — primary component): Copper tripeptide that modulates 4,000+ repair genes, stimulates collagen synthesis (types I, III, IV), balances MMPs/TIMPs, and delivers bioavailable copper to cuproenzymes (lysyl oxidase, SOD1).[2]
• TB-500 (10 mg): Binds G-actin for systemic cell migration, angiogenesis, anti-inflammatory, and anti-fibrotic signalling body-wide.
• BPC-157 (10 mg): Drives local repair via FAK-paxillin pathway, VEGF upregulation, and NO-pathway normalisation; provides additional gut mucosal protection.[3]
• KPV (10 mg — KLOW's distinguishing component): The C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH. Penetrates intestinal epithelial cells, inhibits NF-κB to reduce pro-inflammatory cytokines (IL-6, TNF-α) in gut mucosa, and acts on melanocortin receptors (MC1R, MC3R) for systemic immune modulation.[1]

The 4:1:1:1 ratio prioritises GHK-Cu's broad genomic repair foundation while each supporting peptide contributes a distinct, non-overlapping mechanism.

Good to Know

• KLOW solution is normally blue — this is expected and indicates intact GHK-Cu copper chelation. Do not discard on this basis alone.
• KLOW is particularly suited to recovery contexts involving gut inflammation (NSAID use, IBD flares, stress-related gut dysfunction) where KPV's mucosal protection adds meaningful benefit over the GLOW blend.
• WADA-prohibited — TB-500 and BPC-157 are Category S2 non-approved peptides. Athletes under anti-doping rules must not use KLOW.
• Rotate injection sites daily; document dose, site, and any local reactions.
• What to watch for: Mild injection-site reactions (redness, irritation) are the most common effect; some users report transient lightheadedness from GHK-Cu's mild vasodilatory action. Human clinical data are limited — most evidence is preclinical.
• Gut and immune support: KPV significantly reduced colonic inflammation in experimental colitis, lowering TNF-α, IL-6, and NF-κB activity in intestinal tissue.[1]
• Genomic repair: GHK-Cu modulates 4,000+ genes; 31/66 chronic disease genes shifted toward healthy phenotypes.[2]
• Musculoskeletal repair: BPC-157 and TB-500 components provide local and systemic tissue repair — same evidence base as the Wolverine Stack.[3]
• WADA status: TB-500 and BPC-157 components are prohibited; GHK-Cu and KPV have no explicit WADA prohibition as of 2025 but KLOW as a blend is non-approved.
• For background on KLOW Blend's mechanism, evidence, and safety profile, see What Is KLOW Blend?.

Tips for Best Results

• Maintain adequate dietary protein (1.2–1.6 g/kg) and vitamin C (collagen cofactor) for GHK-Cu's collagen synthesis effects.
• For gut inflammation contexts, a low-FODMAP or anti-inflammatory diet supports KPV's mucosal repair effects.
• Protect skin from UV exposure during GHK-Cu cycles — new matrix formation increases photosensitivity.
• Avoid NSAIDs during KLOW cycles — they counteract BPC-157's NO-pathway and VEGF repair signalling.

Injection Tips

• Clean the vial stopper and injection site with separate alcohol swabs; allow both to air-dry fully before proceeding.
• Using a 29–31 gauge insulin syringe (5/16″ to 1/2″ needle), draw the calculated dose precisely.
• Pinch a fold of skin and insert the needle at 45° into subcutaneous fat (90° is acceptable with a short needle into a well-pinched fold).
• Inject slowly over 2–3 seconds; do not aspirate. Withdraw the needle, apply gentle pressure, and do not rub the site.
• Rotate injection sites (abdomen, thighs, upper arms) and dispose of each syringe in a sharps container immediately after use.